Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Genet Metab ; 121(3): 271-278, 2017 07.
Article in English | MEDLINE | ID: mdl-28579020

ABSTRACT

Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.


Subject(s)
Biomarkers/blood , Leukodystrophy, Globoid Cell/diagnosis , Psychosine/blood , Adolescent , Child , Child, Preschool , Disease Progression , Dried Blood Spot Testing , Humans , Infant , Infant, Newborn , Leukodystrophy, Globoid Cell/drug therapy , Neonatal Screening , Phenotype , Tandem Mass Spectrometry
2.
Mol Genet Metab ; 105(1): 126-31, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22115770

ABSTRACT

PURPOSE: To present clinical, biochemical and molecular information on six new clinically diagnosed Krabbe disease patients and assess the sensitivity of retrospective galactocerebrosidase measurement in their newborn screening samples. METHODS: Medical records were reviewed. Galactocerebrosidase activity was measured in leukocytes and, retrospectively, in the patients' newborn screening cards (stored for 1.4 to 13.5 years). GALC gene mutation analysis was performed. RESULTS: Five patients with Krabbe disease, one of whom also had hydrocephalus, became symptomatic during infancy. A sixth patient presented with seizures and developmental regression at age two and had a protracted disease course. Galactocerebrosidase activity in leukocytes ranged from 0.00 to 0.20 nmol/h/mg protein. Low galactocerebrosidase activity (range: 3.2% to 11.1% of the daily mean), consistent with Krabbe disease, was detected in each of the newborn screening samples. GALC molecular analysis identified six previously unreported mutations and two novel sequence variants. CONCLUSION: Our cases highlight the clinical variability of Krabbe disease. Galactocerebrosidase activity in newborn dried blood spots is a highly sensitive test, even when samples have been stored for many years. The high frequency of private mutations in the GALC gene may limit the use of genetic information for making treatment decisions in the newborn period.


Subject(s)
Leukodystrophy, Globoid Cell/diagnosis , Leukodystrophy, Globoid Cell/pathology , Neonatal Screening , Adolescent , Brain/pathology , Child , Child, Preschool , DNA Mutational Analysis , Dried Blood Spot Testing , Fatal Outcome , Female , Galactosylceramidase/metabolism , Humans , Infant , Infant, Newborn , Leukodystrophy, Globoid Cell/blood , Leukodystrophy, Globoid Cell/enzymology , Magnetic Resonance Imaging , Male , Retrospective Studies
3.
Clin Biochem ; 44(8-9): 704-10, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21382365

ABSTRACT

OBJECTIVE: We aimed to prepare dried-blood spot (DBS) quality control (QC) materials for lysosomal storage disease (LSD) screening tests and to determine optimum blood and DBS storage conditions. METHODS: We compared enzyme activities of five LSD markers in adult blood, umbilical-cord blood, and leukocyte-reduced blood. We measured activities in liquid blood and DBSs after predetermined intervals at controlled temperatures and humidities. RESULTS: Lysosomal-enzyme activity levels in umbilical-cord blood mimicked those in newborn screening samples. Lysosomal-enzyme activities in leukocyte-reduced blood were lower than in LSD-positive patient samples. Enzyme activities were stable in refrigerated liquid blood for 32 days and in frozen DBSs stored at low humidity for a year. Activity losses from DBSs after 34 days at 37±1°C were 35%-66% in low humidity and 61%-100% in high humidity. CONCLUSIONS: Umbilical-cord blood is the preferred matrix for LSD-normal DBS QC materials. Leukocyte-reduced blood is lysosomal enzyme-deficient. Failure to control humidity during DBS storage results in loss of lysosomal-enzyme activities.


Subject(s)
Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/enzymology , Lysosomes/enzymology , Adult , Clinical Enzyme Tests , Female , Humans , Infant, Newborn , Lysosomal Storage Diseases/blood , Neonatal Screening , Pregnancy , Quality Control
SELECTION OF CITATIONS
SEARCH DETAIL
...